Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

944 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN, Stebbins EG, Henson M, O'Young G, Choi SJ, Quon D, Damm D, Reddy M, Ma JY, Haghnazari E, Kapoun AM, Medicherla S, Protter A, Schreiner GF, Kurihara N, Anderson J, Roodman GD, Navas TA, Higgins LS. Nguyen AN, et al. Among authors: ma jy. Exp Cell Res. 2006 Jun 10;312(10):1909-23. doi: 10.1016/j.yexcr.2006.02.026. Epub 2006 Apr 4. Exp Cell Res. 2006. PMID: 16600214
A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.
Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, Kerr I, Stebbins EG, O'Young G, Kapoun AM, Luedtke G, Chakravarty S, Dugar S, Genant HK, Protter AA. Medicherla S, et al. Among authors: ma jy. J Pharmacol Exp Ther. 2006 Jul;318(1):132-41. doi: 10.1124/jpet.105.098020. Epub 2006 Apr 5. J Pharmacol Exp Ther. 2006. PMID: 16597712
Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes.
Medicherla S, Protter AA, Ma JY, Mangadu R, Almirez R, Koppelman B, Kerr I, Navas TA, Movius F, Reddy M, Liu YW, Luedtke G, Perumattam J, Mavunkel B, Dugar S, Schreiner GF. Medicherla S, et al. Among authors: ma jy. J Pharmacol Exp Ther. 2006 Jul;318(1):99-107. doi: 10.1124/jpet.105.097857. Epub 2006 Apr 7. J Pharmacol Exp Ther. 2006. PMID: 16603672
Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC, Higgins LS. Navas TA, et al. Among authors: ma jy. Leukemia. 2006 Jun;20(6):1017-27. doi: 10.1038/sj.leu.2404200. Leukemia. 2006. PMID: 16617327
Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression.
Kapoun AM, Gaspar NJ, Wang Y, Damm D, Liu YW, O'young G, Quon D, Lam A, Munson K, Tran TT, Ma JY, Murphy A, Dugar S, Chakravarty S, Protter AA, Wen FQ, Liu X, Rennard SI, Higgins LS. Kapoun AM, et al. Among authors: ma jy. Mol Pharmacol. 2006 Aug;70(2):518-31. doi: 10.1124/mol.105.021600. Epub 2006 May 17. Mol Pharmacol. 2006. PMID: 16707625
944 results